Neoadjuvant Chemotherapy for Colorectal Cancer Liver Metastases
Author Information
Author(s): Birgit Gruenberger, Werner Scheithauer, Robert Punzengruber, Christoph Zielinski, Dietmar Tamandl, Thomas Gruenberger
Primary Institution: Medical University Vienna
Hypothesis
Does neoadjuvant chemotherapy reduce the risk of recurrence following potentially curative liver resection in colorectal cancer patients?
Conclusion
Neoadjuvant chemotherapy can lead to high response rates and long-term recurrence-free survival in patients with colorectal cancer liver metastases.
Supporting Evidence
- 72% of patients had an objective response to chemotherapy.
- Median recurrence-free survival was 24.7 months for responding patients.
- All patients underwent potentially curative R0 resection.
Takeaway
Giving chemotherapy before surgery helps some cancer patients live longer without their cancer coming back.
Methodology
50 patients received neoadjuvant XELOX or FOLFOX4 chemotherapy for six cycles before surgery.
Limitations
The study was non-randomized and had a relatively small sample size.
Participant Demographics
{"median_age":62,"age_range":"36 to 77","sex_ratio":"34 males, 16 females"}
Statistical Information
P-Value
0.002
Confidence Interval
{"recurrence_free_survival":"95% CI: 4.50 to 44.97","overall_survival":"95% CI: 32.65 to 43.35"}
Statistical Significance
p < 0.004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website